India: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in India

The Indian prophylactic medicaments containing insulin market rose modestly to $X in 2022, growing by 2.8% against the previous year. Over the period under review, consumption saw resilient growth. Over the period under review, the market attained the maximum level at $X in 2020; however, from 2021 to 2022, consumption stood at a somewhat lower figure.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in India

In value terms, prophylactic medicaments containing insulin production rose modestly to $X in 2022 estimated in export price. Over the period under review, production recorded a strong increase. The pace of growth was the most pronounced in 2019 with an increase of 45%. Prophylactic medicaments containing insulin production peaked at $X in 2020; however, from 2021 to 2022, production stood at a somewhat lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports from India

In 2022, after eight years of decline, there was significant growth in shipments abroad of medicaments containing insulin but not antibiotics in measured doses, when their volume increased by 31% to X tons. Over the period under review, exports, however, showed a abrupt decrease. The pace of growth appeared the most rapid in 2013 with an increase of 82% against the previous year. As a result, the exports attained the peak of X tons. From 2014 to 2022, the growth of the exports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin exports surged to $X in 2022. Overall, exports, however, showed a slight downturn. The growth pace was the most rapid in 2013 with an increase of 45% against the previous year. As a result, the exports attained the peak of $X. From 2014 to 2022, the growth of the exports remained at a somewhat lower figure.

Exports by Country

The United States (X tons) was the main destination for prophylactic medicaments containing insulin exports from India, accounting for a 24% share of total exports. Moreover, prophylactic medicaments containing insulin exports to the United States exceeded the volume sent to the second major destination, the UK (X tons), threefold. Peru (X tons) ranked third in terms of total exports with a 6.3% share.

From 2012 to 2022, the average annual rate of growth in terms of volume to the United States totaled -10.1%. Exports to the other major destinations recorded the following average annual rates of exports growth: the UK (-5.1% per year) and Peru (+31.9% per year).

In value terms, the United States ($X), the Netherlands ($X) and Thailand ($X) constituted the largest markets for prophylactic medicaments containing insulin exported from India worldwide, together accounting for 35% of total exports. Nepal, Japan, the UK, Sri Lanka, Peru, Myanmar, Mauritius, South Africa, Senegal and Mali lagged somewhat behind, together comprising a further 24%.

Among the main countries of destination, Myanmar, with a CAGR of +104.6%, recorded the highest growth rate of the value of exports, over the period under review, while shipments for the other leaders experienced more modest paces of growth.

Export Prices by Country

The average prophylactic medicaments containing insulin export price stood at $X per ton in 2022, which is down by -9.4% against the previous year. In general, the export price, however, showed a prominent expansion. The pace of growth appeared the most rapid in 2019 an increase of 52%. Over the period under review, the average export prices reached the maximum at $X per ton in 2020; however, from 2021 to 2022, the export prices failed to regain momentum.

Prices varied noticeably by country of destination: amid the top suppliers, the country with the highest price was Thailand ($X per ton), while the average price for exports to South Africa ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to the Netherlands (+22.7%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports into India

For the eleventh year in a row, India recorded growth in purchases abroad of medicaments containing insulin but not antibiotics in measured doses, which increased by 8.8% to X tons in 2022. In general, imports showed a significant increase. The pace of growth was the most pronounced in 2013 with an increase of 83% against the previous year. Imports peaked in 2022 and are likely to see gradual growth in the near future.

In value terms, prophylactic medicaments containing insulin imports contracted slightly to $X in 2022. The total import value increased at an average annual rate of +4.2% over the period from 2012 to 2022; however, the trend pattern indicated some noticeable fluctuations being recorded throughout the analyzed period. The pace of growth was the most pronounced in 2014 when imports increased by 13%. Imports peaked at $X in 2021, and then contracted in the following year.

Imports by Country

Brazil (X tons), Germany (X tons) and Denmark (X tons) were the main suppliers of prophylactic medicaments containing insulin imports to India, with a combined 80% share of total imports. Belgium, France, Malaysia and Italy lagged somewhat behind, together comprising a further 18%.

From 2012 to 2022, the biggest increases were recorded for Belgium (with a CAGR of +80.3%), while purchases for the other leaders experienced more modest paces of growth.

In value terms, Brazil ($X), Denmark ($X) and Germany ($X) were the largest prophylactic medicaments containing insulin suppliers to India, with a combined 72% share of total imports. Italy, Belgium, France and Malaysia lagged somewhat behind, together comprising a further 26%.

Among the main suppliers, Belgium, with a CAGR of +30.9%, recorded the highest rates of growth with regard to the value of imports, over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

In 2022, the average prophylactic medicaments containing insulin import price amounted to $X per kg, with a decrease of -10.5% against the previous year. Over the period under review, the import price showed a precipitous descent. The pace of growth was the most pronounced in 2019 when the average import price increased by 2.4%. Over the period under review, average import prices reached the peak figure at $X per kg in 2012; however, from 2013 to 2022, import prices remained at a lower figure.

There were significant differences in the average prices amongst the major supplying countries. In 2022, amid the top importers, the country with the highest price was Italy ($X per kg), while the price for Germany ($X per kg) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Italy (-3.9%), while the prices for the other major suppliers experienced a decline.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :